Skip to main content
Premium Trial:

Request an Annual Quote

Biotop to Distribute Sygnis Products in Scandinavia

NEW YORK (GenomeWeb) – Sygnis today announced a non-exclusive deal with Biotop to distribute Sygnis' products in Scandinavia. 

Sygnis has granted Finnish firm Biotop the non-exclusive rights to promote, market, and sell TruePrime and SunScript products. TruePrime products are for primer-free DNA amplification and are based on Sygnis' proprietary DNA primase TthPrimPol and Phi29 polymerase, which enables the amplification of total genomic DNA from amounts of samples down to single cells without the need for random synthetic primers, said Sygnis, which has offices in Germany and Spain. 

SunScript reverse transcriptase kits are for translating RNA into DNA and are engineered for high thermostability. 

Financial and other terms of the agreement were not disclosed. Last week, Sygnis and Welgene Biotech announced a distribution deal covering Taiwan for TruePrime and SunScript.

Biotop provides molecular biology research reagents as well as reagents for next-generation sequencing applications. 

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.